2018
DOI: 10.4274/tjod.28459
|View full text |Cite
|
Sign up to set email alerts
|

YKL-40 in the diagnosis, prediction of prognosis, and platinum sensitivity in serous epithelial ovarian cancer

Abstract: Objective:To evaluate the use of YKL-40 in the discrimination between benign and malignant adnexal mass and to determine its prognostic value in assessing residual tumor after primary cytoreduction and platinum sensitivity in serous epithelial ovarian carcinoma (EOC). Materials and Methods:During the three years from January 2015 to December 2017, a nonconsecutive series of 100 patient (60 malignant, 40 benign) who underwent surgery for an adnexal mass were enrolled in the study. Preoperatively, serum samples … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(1 citation statement)
references
References 33 publications
0
1
0
Order By: Relevance
“…In the past several decades, the ability to recognize patients with early ovarian cancer has gradually improved because of the combined use of cytological analysis, an ultrasonic examination, an endoscopic approach, and other techniques. Therefore, the prognosis of these patients has also improved to some extent, and patients with early-stage ovarian cancer have a 5-year survival of 70-90% (2). However, early-stage ovarian cancer is usually asymptomatic, and the symptoms of late-stage disease are nonspecific (3).…”
Section: Introductionmentioning
confidence: 99%
“…In the past several decades, the ability to recognize patients with early ovarian cancer has gradually improved because of the combined use of cytological analysis, an ultrasonic examination, an endoscopic approach, and other techniques. Therefore, the prognosis of these patients has also improved to some extent, and patients with early-stage ovarian cancer have a 5-year survival of 70-90% (2). However, early-stage ovarian cancer is usually asymptomatic, and the symptoms of late-stage disease are nonspecific (3).…”
Section: Introductionmentioning
confidence: 99%